Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.8%

44 terminated/withdrawn out of 501 trials

Success Rate

87.8%

+1.3% vs industry average

Late-Stage Pipeline

27 trials in Phase 3/4

Results Transparency

55%

175 of 316 completed trials have results

Key Signals

61 recruiting175 with results34 terminated10 withdrawn

Enrollment Performance

Analytics

N/A

308(66.5%)

Phase 2

80(17.3%)

Phase 1

45(9.7%)

Phase 3

14(3.0%)

Phase 4

13(2.8%)

Early Phase 1

3(0.6%)

463Total

N/A(308)

Phase 2(80)

Phase 1(45)

Phase 3(14)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (501)

Showing 20 of 501 trials

NCT07015840Not ApplicableRecruiting

Generalization and Specificity of Visual Learning During Sleep

Role: lead

NCT07007195Early Phase 1Recruiting

Smart Olfaction App to Reduce Relapse

Role: collaborator

NCT05979272Not ApplicableCompleted

TECH App Marijuana Use Intervention for Court-Involved Adolescents

Role: collaborator

NCT07099638Phase 2Not Yet Recruiting

Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation

Role: collaborator

NCT06750107Phase 3Active Not Recruiting

Testing the Efficacy of Safe South Africa

Role: lead

NCT03457675Not ApplicableActive Not Recruiting

Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

Role: collaborator

NCT04281134Not ApplicableActive Not Recruiting

Development of Adaptive Deep Brain Stimulation for OCD

Role: collaborator

NCT01517945Active Not Recruiting

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Role: collaborator

NCT07546799Not ApplicableRecruiting

Growth, Empowerment, and Mindfulness (GEM): A Mindfulness-based Intervention to Address Mental Health in Young Adults With Early Life Adversity

Role: lead

NCT02983773Phase 2Completed

Marijuana's Impact on Alcohol Motivation and Consumption

Role: lead

NCT05480384Phase 2Active Not Recruiting

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Role: lead

NCT06849869Not ApplicableRecruiting

Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change

Role: collaborator

NCT07531641Not ApplicableNot Yet Recruiting

From Screening to Safety: Implementing the AL-STEADI Initiative in Assisted Living Communities

Role: lead

NCT02656706Phase 2Active Not Recruiting

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Role: lead

NCT05096429Not ApplicableCompleted

Preventing Overdose Using Information and Data From the Environment

Role: lead

NCT03667924Not ApplicableCompleted

Utilizing Senior Companions to Enhance Dementia Care

Role: collaborator

NCT05838378Not ApplicableCompleted

Cigarillo Warnings Image Sorting Study

Role: collaborator

NCT05839119Phase 1Terminated

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

Role: lead

NCT03589547Phase 2Completed

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Role: lead

NCT03355976Phase 2Active Not Recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Role: lead